🔗 Share this article

The first new treatments for gonorrhoea in decades are being described as a "huge turning point" in the battle against superbug strains of the infection, according to health experts.

An International Public Health Issue

The sexually transmitted infection are on the rise worldwide, with data suggesting in excess of 82 million instances each year. Notably increased rates are seen in Africa and nations within the World Health Organization's designated area, which encompasses Mongolia and China to New Zealand. Within England, cases have hit a historical peak, while infection numbers across Europe in 2023 were three times higher compared to the rates from 2014.

“The authorization of novel therapies for gonorrhoea is an critical and opportune step in the context of rising global incidence, escalating drug resistance and the highly restricted treatment choices presently on offer.”

Medical experts are particularly alarmed about the surge in treatment-resistant strains. The global health body has classified it as a "priority pathogen". Ongoing monitoring found that the effectiveness of key first-line drugs like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

Two New Therapies Gain Clearance

Zoliflodacin, marketed under the name Nuzolvence, was approved by the US FDA in mid-December for combating gonorrhoea. This infection can lead to serious health problems, including infertility. Scientists hope that targeted use of this new drug will help slow the spread of drug resistance.

Gepotidacin, created by the pharmaceutical company GlaxoSmithKline, was also approved in the same week. This medication, which is additionally indicated for UTIs, was proven in research to be effective against superbug versions of the gonorrhoea bacteria.

A Unique Development Model

This new treatment stemmed from a innovative non-profit model for antibiotic development. The charitable organization Global Antibiotic Research & Development Partnership partnered with the pharmaceutical company its industry partner to develop it.

“This authorization signifies a significant shift in the treatment of superbug gonorrhoea, which until now has been evolving faster than medical innovation.”

Clinical Trial Data and Global Access

Based on findings detailed in a prominent scientific publication, the new drug cured more than 90% of uncomplicated infections. This places it at an similar efficacy with the typical regimen, which involves an injection and a pill. The study involved over 900 volunteers from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its unique model, the non-profit has the authority to license and sell the drug in a wide range of low-income and middle-income countries.

Doctors directly involved have shared positive views. Having a single-dose, oral treatment such as this is hailed as a "revolutionary step" for public health efforts. This is deemed vital to alleviate the strain of the infection for people and to stop the proliferation of untreatable gonorrhoea worldwide.